Spread | 0.05 | ||||
Long position overnight fee Long position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
Overnight fee time | 21:00 (UTC) | ||||
Currency | USD | ||||
Min traded quantity | 1 | ||||
Margin | 20 | ||||
Stock exchange | United States of America | ||||
Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
Prev. Close | 2.18 |
Open | 2.16 |
1-Year Change | 13.09% |
Day's Range | 2.1 - 2.18 |
Lyell Immunopharma, Inc is a T cell reprogramming company. The Company offers T cells to cure patients with solid tumors. Its technologies are designed to be applied in a target and agnostic manner to chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL) and T cell receptor (TCR) therapies to improve the properties of T cells to eradicate solid tumors. It builds a multi-modality product pipeline across solid tumor indications with unmet needs and anticipate having investigational new drug application (IND). It offers Gen-R and Epi-R technology platforms. Its Gen-R is its ex vivo genetic reprogramming technology to overcome T cell exhaustion. Its Epi-R is an ex vivo epigenetic reprogramming technology to create a population of T cells with durable stemness. Epi-R is designed to generate populations of T cells which have this property of durable stemness. It utilizes its Gen-R and Epi-R technology platforms to develop a multi-modality product pipeline.
BRIEF: For the nine months ended 30 September 2021, Lyell Immunopharma Inc revenues increased 44% to $7.8M. Net loss increased 1% to $166.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Stock-based Compensation in SGA increase from $11.3M to $28.4M (expense), General and administrative - Balanc increase of 39% to $28.8M (expense).